| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/24/2015 | US8962002 Alloplastic injectable dermal filler and methods of use thereof |
| 02/24/2015 | US8962000 Microemulsion and sub-micron emulsion process and compositions |
| 02/24/2015 | US8961989 Methods for producing an immune response to tuberculosis |
| 02/24/2015 | US8961988 Compositions and methods for the treatment or prevention of hepatitis B virus infection |
| 02/24/2015 | US8961970 Combination therapy |
| 02/24/2015 | US8961966 Antibodies against ERBB3 and uses thereof |
| 02/24/2015 | US8961963 Pharmacological composition whereby statin and COQ10 compounds are enhanced |
| 02/24/2015 | US8961959 Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| 02/24/2015 | US8961953 Synbiotic mixture |
| 02/24/2015 | US8961949 Polymer-metal complex composite having MRI contrast ability and MRI contrasting and/or antitumor composition using the same |
| 02/24/2015 | US8961948 Molecular surface design of tyrosine-derived polycarbonates for attachment of biomolecules |
| 02/24/2015 | US8961947 Polymeric tissue sealant |
| 02/24/2015 | US8961932 “Micro-patch” for assessment of the local microvasculature and microcirculatory vasoreactivity |
| 02/24/2015 | US8961873 Antinfection protecting healthcare workers to prevent spreading of communicable and nosocomial infections |
| 02/24/2015 | US8961492 System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
| 02/24/2015 | US8961477 Delivery of immune response modifier compounds |
| 02/24/2015 | US8960128 Topical anesthetic composition |
| 02/24/2015 | CA2804165C Piperidinyl pyrimidine amides as kv7 potassium channel openers |
| 02/24/2015 | CA2791165C A conjugate comprising cholesterol linked to tetracycline |
| 02/24/2015 | CA2785200C Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof |
| 02/24/2015 | CA2771403C Quinoline derivative-containing pharmaceutical composition |
| 02/24/2015 | CA2771166C Alcoholic compositions having a lowered risk of acetaldehydemia |
| 02/24/2015 | CA2728328C Treatment of antibiotic-resistant bacteria infection |
| 02/24/2015 | CA2726554C Macrocyclic urea and sulfamide derivatives as inhibitors of tafia |
| 02/24/2015 | CA2712078C Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor |
| 02/24/2015 | CA2703915C P2x3 receptor antagonists for treatment of pain |
| 02/24/2015 | CA2684977C A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant |
| 02/24/2015 | CA2683534C Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same |
| 02/24/2015 | CA2681756C Inhibitors of bruton's tyrosine kinase |
| 02/24/2015 | CA2679206C Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof |
| 02/24/2015 | CA2667867C Resorbable pouches for implantable medical devices |
| 02/24/2015 | CA2658633C Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions |
| 02/24/2015 | CA2656419C Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| 02/24/2015 | CA2648719C Modulators of atp-binding cassette transporters |
| 02/24/2015 | CA2642744C Method and composition for treating chronic obstructive pulmonary disease |
| 02/24/2015 | CA2630717C Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| 02/24/2015 | CA2627423C Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (hdac) inhibitors |
| 02/24/2015 | CA2616508C Pharmaceutical formulation of nitrooxyderivatives of nsaids |
| 02/24/2015 | CA2602324C Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer |
| 02/24/2015 | CA2602294C Heterobicylic inhibitors of hvc |
| 02/24/2015 | CA2548671C Compositions for treating or preventing obesity and insulin resistance disorders |
| 02/24/2015 | CA2507522C Oral drug delivery system |
| 02/24/2015 | CA2489467C Humanized monoclonal antibody hpam4 |
| 02/24/2015 | CA2444907C Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5 |
| 02/23/2015 | CA2824681A1 Nutritional supplements for pregnant women |
| 02/22/2015 | CA2824626A1 2-amino-naphthyridine derivatives |
| 02/19/2015 | WO2015024021A2 Antibacterial compounds |
| 02/19/2015 | WO2015024016A2 2-piperidinyl substituted n,3-dihydroxybutanamides |
| 02/19/2015 | WO2015024011A2 Antibacterial compounds |
| 02/19/2015 | WO2015024010A2 Substituted hydroxamic acid compounds |
| 02/19/2015 | WO2015024000A2 Mitochondrially-targeted electrophilic compounds and methods of use for the treatment of cancer |
| 02/19/2015 | WO2015023976A2 Selective grp94 inhibitors and uses thereof |
| 02/19/2015 | WO2015023967A2 Compositions and methods for modulating dna methylation |
| 02/19/2015 | WO2015023941A1 Oligonucleotides targeting euchromatin regions of genes |
| 02/19/2015 | WO2015023915A1 Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| 02/19/2015 | WO2015023902A2 Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision |
| 02/19/2015 | WO2015023889A1 Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
| 02/19/2015 | WO2015023879A1 Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
| 02/19/2015 | WO2015023871A1 Treatment of alcoholism using ibudilast |
| 02/19/2015 | WO2015023858A2 Uses of phospholipid conjugates of synthetic tlr7 agonists |
| 02/19/2015 | WO2015023839A1 Aryl azetidine derivatives as sphingosine-1 phosphate receptors modulators |
| 02/19/2015 | WO2015023830A1 Treatment and prevention of stroke and other neurological disorders |
| 02/19/2015 | WO2015023827A1 A high-throughput assay for identifying small molecules that modulate amp-activated protein kinase (ampk) |
| 02/19/2015 | WO2015023816A1 (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
| 02/19/2015 | WO2015023797A1 Lipophilic nanoparticles for drug delivery |
| 02/19/2015 | WO2015023790A1 Compositions and methods for treating chronic urticaria |
| 02/19/2015 | WO2015023776A2 Deoxycytidine kinase inhibitors |
| 02/19/2015 | WO2015023770A1 Methods for fine particle manufacture |
| 02/19/2015 | WO2015023767A1 Calcium formate as a supplement to prevent neural tube defects |
| 02/19/2015 | WO2015023710A1 Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| 02/19/2015 | WO2015023703A1 Methods for the treatment of her2 amplified cancer |
| 02/19/2015 | WO2015023691A2 4-methylumbelliferone treatment for immune modulation |
| 02/19/2015 | WO2015023675A2 Extruded immediate release abuse deterrent pill |
| 02/19/2015 | WO2015023664A2 Therapeutic treatment for drug poisoning and addiction |
| 02/19/2015 | WO2015023601A1 Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| 02/19/2015 | WO2015023600A1 Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| 02/19/2015 | WO2015023593A1 Progesterone phosphate analogs and uses related thereto |
| 02/19/2015 | WO2015023524A1 Methods and compositions for increasing the effectiveness of antiviral agents |
| 02/19/2015 | WO2015023289A1 Substituted imidazoles as n-type calcium channel blockers |
| 02/19/2015 | WO2015023281A1 Soluble fiber from yogurt whey |
| 02/19/2015 | WO2015023244A1 Drug with cerebro-protective effect |
| 02/19/2015 | WO2015023226A1 Use of a composition comprising chitosan and a negatively charge polysaccharide for the treament of salivary dysfuntion |
| 02/19/2015 | WO2015023142A1 Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients |
| 02/19/2015 | WO2015023064A1 Method for preparing highly-pure pemetrexed disodium salt |
| 02/19/2015 | WO2015023054A1 Animal model with obsessive compulsive disorder using ninjurin 1 deficiency |
| 02/19/2015 | WO2015022962A1 Lipid metabolism accelerator |
| 02/19/2015 | WO2015022926A1 Novel fused pyrimidine compound or salt thereof |
| 02/19/2015 | WO2015022909A1 Ghg-containing composition and fat absorption inhibitor using same |
| 02/19/2015 | WO2015022907A1 Drug containing cationized chitosan |
| 02/19/2015 | WO2015022831A1 Composition for promoting estrogen and testosterone secretion, aromatic composition thereof, and aromatic tool thereof |
| 02/19/2015 | WO2015022830A1 Composition for promoting estrogen secretion, aromatic composition, and aroma tool |
| 02/19/2015 | WO2015022703A1 A stable pharmaceutical composition of fesoterodine hydrochloride |
| 02/19/2015 | WO2015022664A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022663A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022662A1 Compounds and compositions as inhibitors of mek |
| 02/19/2015 | WO2015022657A1 Pharmaceutical combinations |
| 02/19/2015 | WO2015022631A1 Substituted biphenyl compounds as calcium sensing receptor modulators |
| 02/19/2015 | WO2015022613A1 Compositions and methods for the treatment of diabetes and pre-diabetes |
| 02/19/2015 | WO2015022609A1 Combination therapy for the treatment of cancer |
| 02/19/2015 | WO2015022560A1 Stable pharmaceutical composition containing bisoprolol and ramipril |